Lucio Crinò, MD, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer
Lucio Crinò, MD
Advertisement
Articles by Lucio Crinò, MD
Advertisement
Latest Updated Articles
Dr. Crinò on Crizotinib in ALK-Positive NSCLCPublished: October 1st 2013 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Around the Helix: Cell and Gene Therapy Company Updates – October 29, 2025
2
Quarter Century Update: Future Predictions for the Field
3
Naji Gehchan, MD, MBA, on Evaluating CAR-T KYV-101 for Generalized Myasthenia Gravis
4
Quarter Century Update: What Does the Field Need Most Right Now?
5
